"Vasoconstrictor Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used to cause constriction of the blood vessels.
| Descriptor ID |
D014662
|
| MeSH Number(s) |
D27.505.954.411.793
|
| Concept/Terms |
Vasoconstrictor Agents- Vasoconstrictor Agents
- Agents, Vasoconstrictor
- Vasoconstrictor Drugs
- Drugs, Vasoconstrictor
- Vasoconstrictors
- Vasoactive Agonists
- Agonists, Vasoactive
- Vasopressor Agents
- Agents, Vasopressor
|
Below are MeSH descriptors whose meaning is more general than "Vasoconstrictor Agents".
Below are MeSH descriptors whose meaning is more specific than "Vasoconstrictor Agents".
This graph shows the total number of publications written about "Vasoconstrictor Agents" by people in this website by year, and whether "Vasoconstrictor Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 |
| 1996 | 4 | 0 | 4 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 2 | 2 | 4 |
| 2001 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 4 | 3 | 7 |
| 2005 | 4 | 2 | 6 |
| 2006 | 2 | 3 | 5 |
| 2007 | 1 | 3 | 4 |
| 2008 | 1 | 3 | 4 |
| 2009 | 0 | 4 | 4 |
| 2010 | 3 | 3 | 6 |
| 2011 | 1 | 2 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 3 | 4 |
| 2015 | 3 | 0 | 3 |
| 2016 | 2 | 3 | 5 |
| 2017 | 2 | 2 | 4 |
| 2018 | 3 | 4 | 7 |
| 2019 | 4 | 4 | 8 |
| 2020 | 4 | 5 | 9 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 4 | 4 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vasoconstrictor Agents" by people in Profiles.
-
Controversies in terlipressin and transplantation in the United States: How do we MELD the two? Liver Transpl. 2024 Jul 01; 30(7):753-759.
-
Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin. Liver Transpl. 2024 04 01; 30(4):347-355.
-
Management of Vasoplegic Shock in the Cardiovascular Intensive Care Unit after Cardiac Surgery. Crit Care Clin. 2024 Jan; 40(1):73-88.
-
The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome. Kidney360. 2023 08 01; 4(8):1030-1038.
-
Terlipressin Treatment Is Associated With Reversal of Hepatorenal Syndrome in Patients With Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3455-3457.e3.
-
Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure. Aliment Pharmacol Ther. 2022 10; 56(8):1284-1293.
-
Effect of Fluid Bolus Administration on Cardiovascular Collapse Among Critically Ill Patients Undergoing Tracheal Intubation: A Randomized Clinical Trial. JAMA. 2022 07 19; 328(3):270-279.
-
Evaluation of the Addition of Angiotensin II in Patients With Shock After Cardiac Surgery at a Veterans Affairs Medical Center. Ann Pharmacother. 2023 02; 57(2):141-147.
-
Administration of vasopressors through peripheral venous catheters. CMAJ. 2022 05 30; 194(21):E739.
-
Hepatorenal syndrome: a historical appraisal of its origins and conceptual evolution. Kidney Int. 2021 06; 99(6):1321-1330.